Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.00 -0.76% 1,050.00 1,044.00 1,066.00 1,080.00 1,036.00 1,052.00 16,796 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 86.4 12.6 20.0 52.5 520

Ergomed plc Exercise of Options

25/11/2021 6:59am

UK Regulatory (RNS & others)

Ergomed (LSE:ERGO)
Historical Stock Chart

From May 2021 to May 2022

Click Here for more Ergomed Charts.


RNS Number : 5095T

Ergomed plc

25 November 2021


Exercise of Share Options and Total Voting Rights

Guildford, UK - 25 November 2021: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 11,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 26 November 2021. Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission on 26 November 2021, the total number of ordinary shares with voting rights in issue will be 49,132,071. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.



 Ergomed plc                                           Tel: +44 (0) 1483 402 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
 Numis Securities Limited (Nominated Adviser            Tel: +44 (0) 20 7260 
  and Joint Broker)                                                     1000 
 Freddie Barnfield / Matthew O'Dowd 
 James Black (Broker) 
  Peel Hunt LLP (Joint Broker)                          Tel: +44 (0) 20 7418 
  James Steel / Dr Christopher Golden                                   8900 
 Consilium Strategic Communications                     Tel: +44 (0) 20 3709 
 Chris Gardner / Matthew Neal           
 Angela Gray 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 25, 2021 01:59 ET (06:59 GMT)

1 Year Ergomed Chart

1 Year Ergomed Chart

1 Month Ergomed Chart

1 Month Ergomed Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220525 15:58:28